Home
overview

What is this event about?

Inhaled therapeutics for COPD

 

About the conference

This year, SMi offers its 2nd annual conference COPD: Novel Therapeutics and Management Strategies.  COPD was the 6th biggest killer in the world in 1990, and is forecast to be the 4th biggest killer by 2030.  At present, one person every 15 seconds dies of COPD worldwide.  In the Western world, it is the only major cause of death that is on the increase.  Despite this, COPD tends to be neglected in terms of drug discovery & development when compared to Asthma.

Taking place in Munich, Germany, this conference will look at the latest in R&D, partnering options and drug development strategies for developing novel therapeutics for COPD.  It will also focus on the challenges of developing a successful COPD pipeline, on opportunities for addressing COPD in Asia and on COPD management strategies.

The conference aims to address the imbalance in research and industry focus between Asthma and COPD, and place the spotlight firmly on COPD alone.

Why not attend the associated workshop as well?

Associated with the conference there will be a half-day interactive workshop on "Drugs and Devices and Inhalation Therapy", taking place on 16th November.  It will cover inhaled treatments for COPD, with a particular focus on the design of clinical trials and on techniques and devices for inhaled therapeutics.  This will be led by Sabine Häußermann, Director of Business Development, Inamed Research.  To see more information about the workshop, please see the COPD 2010 workshop page.

Keen to see the detailed programme?  Click here.

Want to download the brochure?  Click here.

Register for the event here!

Group discounts available - click here

 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know: contact the Conference Producer.

For sponsorship and exhibitioning opportunities,  contact our Sponsorship Department 

Why should you attend this event?

What you will learn about

  • Developing novel therapeutics: various perspectives on the best strategies to develop new COPD therapeutics and build a successful COPD pipeline
  • New approaches and new targets: the latest developments in R&D
  • Clinical studies for COPD: proof of concept studies and innovative design of trials to optimise success in developing new COPD treatments 
  • Biomarkers: identifying and developing biomarkers for COPD
  • Animal models: the relevance and limitations of the latest animal models
 COPD managment strategies
 COPD treatment

How you will benefit

Examine the current state of the market for COPD therapeutics

Discover the latest research and technologies

Study the different approaches being taken to develop new COPD treatments

Network with leaders from business and research in the COPD field

Who should attend this event?

Chief Executives, Executive Directors, Vice Presidents, Heads, Senior Scientists, Team leaders of

  • COPD
  • Respiratory Therapeutic Area
  • Respiratory Science
  • Respiratory Technology
  • Global Product Advocacy (Respiratory)
  • Research & Development
  • Inflammation
  • Allergy and Respiratory
  • Global Discovery Medicine
  • Global Medical Science
  • Clinical Therapy Area
  • Respiratory & Inflammation Therapeutic area
  • Respiratory Medical Affairs
  • Clinical Research and Development
  • Clinical & Regulatory Affairs
  • Drug Discovery
  • Drug Delivery
  • Inhalation Drug Delivery
  • Preclinical Development

Delegates at our 2009 COPD conference came from across the world

Former delegates at 2009 COPD management conference

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Christopher Meade

Christopher Meade, Head Global Licensing Respiratory, Boehringer Ingelheim

9:10 OPENING KEYNOTE

Christopher Meade

Christopher Meade, Head Global Licensing Respiratory, Boehringer Ingelheim

  • Why is partnering so important for developing COPD products?
  • Examples of partnering in COPD product development
  • Trends and changes in the partnering process
  • 9:50 Building a novel biologics COPD pipeline

    Donna Finch

    Donna Finch, Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune

  • Understanding the opportunities and therapeutic options in COPD for biologics
  • Making the optimal antibody drugs, and validating promising targets
  • New insight into our more advanced programmes
  • 10:30 Novel therapeutics for acute exacerbations of COPD

    Liz Hardaker

    Liz Hardaker, Research Investigator I, Novartis

  • Models for acute exacerbations 
  • Identifying potential novel therapeutics 
  • Assessment in the clinic
  • 11:10 Morning coffee

    11:40 Is there a role for retinoids in COPD-emphysema?

    Alexis Rames

    Alexis Rames, Translational Medicine Leader, Inflammation/Respiratory Early Development, Roche

  • Biological effects of retinoic acids in lungs suggest a disease-modifying activity in emphysema
  • A Gamma-selective Retinoic Acid Agonist repairs lung tissue and improves lung function in animal models of emphysema
  • Altering lung structure or slowing emphysema progression?
  • A pilot study in AATD with Palovarotene
  • What next?... TESRA in smoke-induced emphysema
  • 12:20 Bronchodilators in the treatment of COPD: extracting novelty and delivering real patient benefit

    Alan Young

    Alan Young, Discovery Director, Early Development and Senior Principal Scientist, AstraZeneca

  • How do the emerging new compounds claim to be differentiated?
  • How will they impact the market and will the regulatory hurdles be the same?
  • Single or combination usage: where are the advantages?
  • Multiple pharmacologies in one molecule: the way to the ultimate treatment? 
  • Alternative approaches: essential contingencies in a risk averse world?
  • 13:00 Networking lunch

    14:00 Discovery, structure-activity relationships and efficacy of novel BK-channel openers

    Antonio Nardi

    Antonio Nardi, Associate Scientific Director, Grünenthal

  • NeuroSearch has identified a number of BK channel modulators as potential development candidates for the treatment of COPD
  • Their specific effect on BK channels expressed in mammalian cells or in Xenopus oocytes was characterised by using electrophysiological techniques
  • The most promising compounds were further validated on prepared vagus nerves from guinea pigs or humans on which they inhibited the sensory activity
  • Some compounds showed significant inhibition in in-vivo animal models such as
  • A rat smoke model measuring number of goblet cells
  • Two rat bronchoconstriction models induced either by adenosine agonist and histamine.  The compounds were dosed intra trachea and by inhalation
  • 14:40 KEYNOTE ADDRESS

    René van der Merwe

    René van der Merwe, Director - Clinical Development, Respiratory and Inflammation, MedImmune

  • Cigarette smoking and air pollution are the main causes of COPD
  • Changes in the airways and lung parenchyma are characterised by inflammation and lung tissue destruction
  • The basis of such inflammation is not clear but a number of pathways are being investigated
  • How to interfere with the different forms of inflammation will be explored in this presentation
  • 15:20 Afternoon tea

    15:50 aTPI 1100: an oligonucleotide approach for phosphodiesterase inhibition in COPD

    Paolo Renzi

    Paolo Renzi, Chief Medical Officer, Topigen

  • Oligonucleotide therapeutics for respiratory diseases
  • Advantages and challenges with these approaches
  • TPI-1100: antisense to PDE4B, 4D and 7A for the therapy of COPD
  • 16:30 KEYNOTE ADDRESS

    Yu-Zhen Liu

    Yu-Zhen Liu, Project Manager, Respiratory & Inflammation Asia Strategy Team, AstraZeneca

  • Approaches to understanding COPD in Asia 
  • Partnerships established for translational science programmes
  • AstraZeneca's emerging portfolio in Asia
  • 17:10 Chairman’s closing remarks and close of day one

    8:30 Re-registration and coffee

    9:00 Chairman's opening remarks

    Alasdair Gaw

    Alasdair Gaw, Director of Translational Science, Respiratory and Inflammation, AstraZeneca

    9:10 KEYNOTE ADDRESS

    Nigel Dallow

    Nigel Dallow, Director of Statistics, Discovery Biometrics Respiratory, GlaxoSmithKline

  • Efficient design/analysis strategies in early phase PoC studies
  • Dealing with uncertainty in endpoints/biomarkers
  • Benefit and application of adaptive designs
  • 9:50 Physical activity monitoring in multi-centre pharmacological clinical trials

    Idelle Weisman

    Idelle Weisman, Independent Medical Consultant, Pharmaceutical and Respiratory Equipment Industries, (formerly Medical Director, Pfizer)

  • The rationale for objectively measuring physical activity in multi-centre clinical trials in COPD
  • Challenges associated with using activity monitors in multi-centre clinical trials
  • An integrative approach which incorporates an individualised activity plan, behavioural modification and activity monitor feedback in combination with pharmacologic intervention to encourage patients to be more physically active and enjoy a healthier lifestyle
  • 10:30 Morning coffee

    11:00 COPD begins in childhood?

    Zorica Zivkovic

    Zorica Zivkovic, Associate Professor in Paediatrics, Medical Academy-US Medical School, Belgrade, Serbia

  • Early life events that may lead to chronic lung disease
  • Effects of environmental factors on mother and child
  • Genetic background for development of chronic lung disease
  • What we can and should do?
  • 11:40 Panel & Audience Discussion

    12:20 Networking lunch

    13:50 Biomarker development in COPD

    Alasdair Gaw

    Alasdair Gaw, Director of Translational Science, Respiratory and Inflammation, AstraZeneca

  • Identifying patient phenotypes
  • Determining efficacy in phase 1/2 studies
  • Validation for regulatory authorities
  • 14:30 KEYNOTE ADDRESS

    Birgit Jung

    Birgit Jung, Director, Pulmonary Diseases Research, Boehringer Ingelheim

  • Overview on animal models of COPD
  • Relevance and limitations of animal models
  • Potential of COPD models for drug evaluation
  • 15:10 Development of Bimosiamose in COPD: How to translate anti-inflammatory potential into clinical benefit

  • Bimosiamose the most advanced pan-selecting antagonist, as a new anti-inflammatory therapeutic option in COPD
  • Status of clinical development of Bimosiamose
  • Challenges of translating anti-inflammatory potential into clinical benefit
  • Daniel Bock

    Daniel Bock, Director Preclinical & Clinical R&D, Revotar

    Wolfgang Meyer-Sabellek

    Wolfgang Meyer-Sabellek, Chief Medical Officer, Revotar

    15:50 Chairman’s closing remarks

    16:00 Networking tea and coffee break

    16:30 End of conference

    +

    Workshops

    Drugs and Devices in Inhalation Therapy
    Workshop

    Drugs and Devices in Inhalation Therapy

    Hilton Munich City
    16th November 2010
    Munich, Germany

    Hilton Munich City

    Rosenheimer Strasse 15
    Munich 81667
    Germany

    Hilton Munich City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.